LLY
HealthcareEli Lilly and Company
$1041.51
$-38.85 (-3.60%)
Jan 5, 2026
Price History (1Y)
Analysis
Eli Lilly and Company is a healthcare company operating in the Drug Manufacturers - General industry within the Healthcare sector. With a market capitalization of $933.67B, it is one of the largest companies in its sector. The company has a significant scale with 47,000 employees. The financial health of Eli Lilly and Company appears strong, with notable profitability metrics. The company's gross margin stands at 83.0%, operating margin at 48.3%, and profit margin at 31.0%. In terms of returns, the return on equity is 96.5% and the return on assets is 17.6%. From a balance sheet perspective, the debt to equity ratio is 178.52, while the company has $9.91B in cash and $42.58B in debt. The valuation context for Eli Lilly and Company shows a P/E ratio of 52.92 (TTM) and forward P/E of 31.93. The revenue growth year-over-year is 53.9%, with earnings growth at 480.4%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd; Strategic Collaboration with Eli Lilly to advance development of its myeloid engager platform for autoimmune disease, as well as Strategic partnership with NVIDIA Corporation. The company also has a research collaboration agreement with Insilico Medicine for the development of advance therapies. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Visit website →Key Statistics
- Market Cap
- $933.67B
- P/E Ratio
- 52.92
- 52-Week High
- $1111.99
- 52-Week Low
- $623.78
- Avg Volume
- 3.46M
- Beta
- 0.35
- Dividend Yield
- 58.00%
Company Info
- Industry
- Drug Manufacturers - General
- Exchange
- NYQ
- Country
- United States
- Employees
- 47,000